Developping a a Brain-controlled Art App to Ease Residual Symptoms of Depression
NCT ID: NCT06098469
Last Updated: 2024-11-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
22 participants
INTERVENTIONAL
2024-10-10
2025-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Real-time Biofeedback With 7-Tesla MRI for Treatment of Depression
NCT04138680
Brain Changes in Severely Depressed Patients Before and After Treatment With Electroconvulsive Therapy
NCT02715986
NEUROFEEDSTIM : Therapeutic Use of Neurofeedback in Depression in Association With TMS
NCT03279913
Neurofeedback for Treatment Resistant Depression
NCT03428828
Neurofeedback In Treatment Resistant Depression
NCT04078438
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Neurofeedback
10 neurofeedback sessions + depressive rating scales
Neurofeedback sessions
10 Neurofeedback sessions, psychiatric interview (MADRS, QIDS-C16), reverse-correlation task, QIDS-SR16, EQ-5D-5L, motivation assessment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Neurofeedback sessions
10 Neurofeedback sessions, psychiatric interview (MADRS, QIDS-C16), reverse-correlation task, QIDS-SR16, EQ-5D-5L, motivation assessment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Information and signed informed consent
* Patients with a diagnosis of major depressive episode in remission
* MADRS score between 14 and 22
* Patients with residual symptoms as assessed by MADRS items
* No cognitive impairment.
* Right-handed
Exclusion Criteria
* Subjects unlikely to cooperate with the study and/or poor cooperation anticipated by the investigator
* Pregnant women
* Subjects in the exclusion period of another study or is on the "national volunteer list".
* Subjects with another psychiatric pathology (bipolar mood disorder, psychosis, obsessive-compulsive disorder, addictive pathology, schizophrenia)
* Subjects under a protective measure such as guardianship or safeguard of justice.
25 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Besancon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emmanuel HAFFEN, MD PhD
Role: PRINCIPAL_INVESTIGATOR
CHU de Besançon
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Besançon
Besançon, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
API/2019/102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.